📊 BLCO Key Takeaways
Investment Thesis
Bausch & Lomb faces severe profitability challenges despite 6.5% revenue growth, with negative net income of -$360M and negative free cash flow of -$66M indicating operational stress. The company's interest coverage ratio of 0.3x is critically low, suggesting difficulty servicing its $5B debt load, while negative returns on equity (-5.6%) and assets (-2.6%) demonstrate poor capital efficiency.
BLCO Strengths
- Revenue growing 6.5% year-over-year, showing demand for ophthalmic products
- Reasonable current ratio of 1.55x provides near-term liquidity buffer
- Moderate debt-to-equity ratio of 0.78x shows manageable leverage relative to equity base
BLCO Risks
- Critically low interest coverage ratio of 0.3x indicates severe difficulty servicing $5B long-term debt obligations
- Negative free cash flow of -$66M despite positive operating cash flow suggests capital expenditures exceed operating cash generation capacity
- Negative net margin of -7.1% and negative net income of -$360M indicate the company is currently unprofitable at the bottom line
- Negative ROE and ROA indicate shareholder capital is being destroyed rather than efficiently deployed
Key Metrics to Watch
- Path to operating margin expansion above 2.2% to achieve profitability
- Free cash flow recovery from negative to positive territory
- Interest coverage ratio improvement toward minimum 2.0x threshold for debt sustainability
BLCO Financial Metrics
💡 AI Analyst Insight
Bausch & Lomb Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BLCO Profitability Ratios
BLCO vs Default Sector
How Bausch & Lomb Corp compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BLCO Balance Sheet & Liquidity
BLCO 5-Year Financial Trend
5-Year Trend Summary: Bausch & Lomb Corp's revenue has grown significantly by 35% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.74 indicates the company is currently unprofitable.
BLCO Growth Metrics (YoY)
BLCO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2B | $4.0M | $0.01 |
| Q2 2025 | $1.2B | -$62.0M | $-0.18 |
| Q1 2025 | $1.1B | -$167.0M | $-0.48 |
| Q3 2024 | $1.0B | $4.0M | $0.01 |
| Q2 2024 | $1.0B | -$32.0M | $-0.09 |
| Q1 2024 | $931.0M | -$90.0M | $-0.26 |
| Q3 2023 | $942.0M | $7.0M | $0.02 |
| Q2 2023 | $941.0M | $5.0M | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BLCO Capital Allocation
BLCO SEC Filings
Access official SEC EDGAR filings for Bausch & Lomb Corp (CIK: 0001860742)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BLCO
What is the AI rating for BLCO?
Bausch & Lomb Corp (BLCO) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLCO's key strengths?
Revenue growing 6.5% year-over-year, showing demand for ophthalmic products. Reasonable current ratio of 1.55x provides near-term liquidity buffer.
What are the risks of investing in BLCO?
Critically low interest coverage ratio of 0.3x indicates severe difficulty servicing $5B long-term debt obligations. Negative free cash flow of -$66M despite positive operating cash flow suggests capital expenditures exceed operating cash generation capacity.
What is BLCO's revenue and growth?
Bausch & Lomb Corp reported revenue of $5.1B.
Does BLCO pay dividends?
Bausch & Lomb Corp does not currently pay dividends.
Where can I find BLCO SEC filings?
Official SEC filings for Bausch & Lomb Corp (CIK: 0001860742) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLCO's EPS?
Bausch & Lomb Corp has a diluted EPS of $-1.02.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.